Literature DB >> 10967507

Medical treatment: does it influence the natural course of inflammatory bowel disease?

.   

Abstract

It is difficult to predict the clinical course of inflammatory bowel disease (IBD). Moderately sick Crohn's disease (CD) patients and patients with distal ulcerative colitis (UC) may get better even without medical or surgical treatment. Once better, they may continue in remission even without treatment. If they are not treated, there are several factors that predict whether they will maintain remission. Most patients will probably alternate between remission and relapse, with 10% having a relapse-free course after 10 years, and only 1% having a continuously active course. Frequent relapses initially are associated with active disease later on, but the disease activity course is independent of the response to the initial medical treatment. There is a cumulative frequency of operation of 50-80% and of reoperation of 33% in CD, which suggests that CD has a more serious course than UC. In UC, the overall probability of surgery is 33% for pancolitis and 10% for proctitis within 5 years of diagnosis, and the majority of patients are operated on within the first few years. Maintenance treatment with sulphasalazine (SASP) and 5-aminosalicylic acid (5-ASA) in UC has reduced relapse rates to about half over a 1-year follow-up period. The use of 5-ASA for maintenance of CD has been shown to result in only a modest therapeutic gain, while azathioprine and 6-mercaptopurine (6-MP) improve the relapse frequency for at least 3 years whilst on treatment. Changes in disease distribution in UC are part of the natural course of the disease, which should have implications for medical treatment strategies, and affects the risk of colectomy and colonic cancer. Certain enviromental factors are thought to determine disease activity and disease outcome in UC and CD. Patient compliance with prescribed medication and clinical check-ups must be considered another non-specific variable affecting the clinical outcome. IBD frequently requires potent medication with side effects that limit patients' acceptance. Such patients often resort to medicinal herbs, acupuncture, and homeopathy, which may alter the expected course.

Entities:  

Year:  2000        PMID: 10967507     DOI: 10.1016/s0953-6205(00)00091-1

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  Effects of Changtai granules, a traditional compound Chinese medicine, on chronic trinitrobenzene sulfonic acid-induced colitis in rats.

Authors:  Yong-Bing Cao; Jun-Dong Zhang; Ya-Ying Diao; Lan Yan; De-Jun Wang; Xin-Ming Jia; Ping-Hui Gao; Ming-He Cheng; Zheng Xu; Yan Wang; Yuan-Ying Jiang
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

3.  Intestinal protein expression profile identifies inflammatory bowel disease and predicts relapse.

Authors:  Jun Shen; Yuqi Qiao; Zhihua Ran; Tianrong Wang; Jiangtao Xu; Jinsun Feng
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

4.  Clinical course of intestinal Behcet's disease during the first five years.

Authors:  Yoon Suk Jung; Jae Hee Cheon; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim
Journal:  Dig Dis Sci       Date:  2012-08-17       Impact factor: 3.199

5.  Downregulation of electroacupuncture at ST36 on TNF-alpha in rats with ulcerative colitis.

Authors:  Li Tian; Yu-Xin Huang; Min Tian; Wei Gao; Qing Chang
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

6.  Insufficient knowledge of korean gastroenterologists regarding the vaccination of patients with inflammatory bowel disease.

Authors:  Yoon Suk Jung; Jung Ho Park; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Dong Il Park
Journal:  Gut Liver       Date:  2014-05       Impact factor: 4.519

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.